Leuprorelin Drugs Market Report 2025

The leuprorelin drug market size has grown strongly in recent years. It will grow from $2.69 billion in 2024 to $2.88 billion in 2025 at a compound annual growth rate (CAGR) of 7%. The growth during the historic period can be attributed to increasing healthcare expenditure, a rise in gynecological disorders, expansion of government initiatives, growth in the number of specialty clinics, and rising infertility rates.

The leuprorelin drug market size is expected to see strong growth in the next few years. It will grow to $3.72 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth during the forecast period can be attributed to the rising incidence of prostate cancer, increasing demand for in vitro fertilization (IVF) treatments, growing demand for breast cancer drugs, expansion of gender-affirming treatments, and increasing digitalization in healthcare. Key trends in this period include advancements in biodegradable implant research, integration of artificial intelligence (AI), development of personalized hormone therapies, innovations in extended-release formulations, and progress in peptide synthesis.

The rising prevalence of prostate cancer is expected to drive the growth of the leuprorelin drugs market. Prostate cancer is a type of cancer that develops in the prostate gland, a small gland located below the bladder and in front of the rectum in men. The increasing prevalence is largely attributed to the aging population, as the risk of developing prostate cancer rises significantly with age. Leuprorelin drugs aid in the treatment of prostate cancer by regulating hormone levels and slowing tumor growth, thereby improving patient outcomes, reducing cancer progression, and enhancing quality of life. For example, according to the National Health Service in November 2024, new prostate cancer cases reached 54,732 in 2022, an increase of 11,354 cases compared to 2021. Therefore, the rising incidence of prostate cancer is fueling the growth of the leuprorelin drugs market.

Key players in the leuprorelin drugs market are focusing on advanced formulations, such as ready-to-use injections, to improve patient convenience, enhance treatment adherence, and reduce preparation errors. Ready-to-use injections are pre-filled, sterile formulations of leuprolide acetate that eliminate the need for reconstitution, simplifying administration for both healthcare providers and patients. For instance, in June 2025, Avenacy Inc., a US-based biopharmaceutical company, launched a ready-to-use leuprolide acetate injection for the palliative treatment of advanced prostate cancer. This formulation provides a convenient and reliable treatment option, eliminates the need for manual mixing, reduces the risk of dosing errors and contamination, and ensures consistent therapeutic efficacy. It functions as a gonadotropin-releasing hormone (GnRH) agonist, initially increasing and then significantly lowering testosterone levels, which helps slow the growth of hormone-sensitive cancer cells.

In April 2022, Accord BioPharma Inc., a US-based pharmaceutical company, partnered with Foresee Pharmaceuticals Co. Ltd. to launch long-acting leuprolide for advanced prostate cancer treatment. This collaboration aims to expand access to long-acting hormone therapy, enhance treatment options for patients, and commercialize CAMCEVI, a novel ready-to-inject leuprolide formulation developed using Foresee’s proprietary SIF technology. Foresee Pharmaceuticals Co. Ltd., based in Taiwan, specializes in developing long-acting leuprorelin drugs.

Major players in the leuprorelin drugs market are AbbVie Inc., Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Sandoz Group AG, Sun Pharmaceutical Industries Limited, Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zydus Lifesciences Limited, Lupin Limited, Livzon Pharmaceutical Group Inc., Alkem Laboratories Limited, Daewoong Pharmaceutical Co. Ltd., Emcure Pharmaceuticals Limited, Gland Pharma Limited, Tolmar Pharmaceuticals Inc., Beijing Biote Pharmaceutical Co. Ltd., Accord Healthcare Limited, Intas Pharmaceuticals Limited, Foresee Pharmaceuticals Co Ltd., and Samarth Life Sciences Private Limited.

North America was the largest region in the leuprorelin drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in leuprorelin drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the leuprorelin drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

Leuprorelin drugs are synthetic gonadotropin-releasing hormone (GnRH) agonists used to suppress the production of sex hormones. They work by initially stimulating and subsequently downregulating the pituitary gland’s secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), resulting in decreased production of sex hormones such as testosterone and estrogen. This hormonal regulation significantly reduces the body’s natural sex hormone levels, making these drugs effective for various medical conditions.

The primary types of leuprorelin drugs include injections, tablets, and implants. Leuprorelin injections are formulations of leuprorelin acetate administered subcutaneously or intramuscularly to suppress sex hormones. They are used in the treatment of prostate cancer, endometriosis, breast cancer, and early puberty. These injections are available in different dosage forms, including depot injections and ready-to-use injections, and are administered via intramuscular or subcutaneous routes. Leuprorelin drugs are applied in conditions such as advanced prostate cancer, central precocious puberty, uterine fibroids, endometriosis, and others, serving a range of end users including home care settings, hospitals, and specialty clinics.

The leuprorelin drugs market research report is one of a series of new reports that provides leuprorelin drugs market statistics, including the leuprorelin drugs industry's global market size, regional shares, competitors with a leuprorelin drugs market share, detailed leuprorelin drugs market segments, market trends and opportunities, and any further data you may need to thrive in the leuprorelin drugs industry. This leuprorelin drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The leuprorelin drugs market consists of sales of products including depot formulations, microparticle suspension, prefilled syringes, and leuprolide acetate kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.